{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T22:20:53Z","timestamp":1757456453141},"reference-count":43,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2011,2,1]],"date-time":"2011-02-01T00:00:00Z","timestamp":1296518400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2011,3]]},"abstract":"<jats:sec><jats:label \/><jats:p> <jats:bold>WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003Renin\u2010angiotensin\u2010aldosterone system inhibition confers cardio\u2010renal protection and may be achieved by monotherapy with an angiotensin enzyme converting inhibitor (ACEI) or an angiotensin\u2010II receptor blocker (ARB).<\/jats:p><jats:p>\u2022\u2003Dual ACEI and ARB therapy has been examined in major clinical trials with conflicting results.<\/jats:p><jats:p>\u2022\u2003The prescribing pattern of dual therapy in general primary care population is not known.<\/jats:p><jats:p> <jats:bold>WHAT THIS STUDY ADDS<\/jats:bold> <\/jats:p><jats:p>\u2022\u2003An increase in the co\u2010prescribing of ACEIs and ARBs was observed in the Irish primary care population.<\/jats:p><jats:p>\u2022\u2003Co\u2010prescribing of ACEIs and ARBs in the primary care population did not appear to be influenced by results from major clinical trials.<\/jats:p><jats:p>\u2022\u2003ACEIs and ARBs were more likely to be co\u2010prescribed in special cohorts of the population with diabetes, hypertension and heart failure.<\/jats:p><\/jats:sec><jats:sec><jats:title>AIMS<\/jats:title><jats:p>(i) To examine the trends in co\u2010prescribing of angiotensin converting enzyme inhibitor (ACEI) and angiotensin\u2010II receptor blocker (ARB) therapy and (ii) to examine the influence of major clinical trials (CALM, COOPERATE, VALIANT and ONTARGET) on co\u2010prescribing.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>The Irish HSE\u2010Primary Care Reimbursement Services database was used to identify patients \u226516 years old co\u2010prescribed ACEIs and ARBs between January 2000 and April 2009 (<jats:italic>n<\/jats:italic>= 266\u2003554 prescriptions). The rate of prescribing per 1000 general medical services (GMS) scheme population was calculated for each month. Patients with diabetes, hypertension, heart failure and ischaemic heart disease were also identified by prescribing of certain medications. A linear trend test was used to examine prescribing trends. Logistic regression was used to examine prescribing according to patient characteristics. The effects of the major trials on prescribing were examined using segmented regression analysis for 12 months pre\u2010 and post\u2010trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>There was a significant linear trend in overall ACEI and ARB co\u2010prescribing over the study period (<jats:italic>P<\/jats:italic> &lt; 0.001). Rate of co\u2010prescribing in January 2000 and April 2009 was 0.16 and 5.72, per 1000 eligible population, respectively. Those 45\u201364 years old (OR = 2.88, 95% confidence interval (CI) 2.71, 3.06) and \u226565 years (OR = 2.52, 95% CI 2.36, 2.68) were more likely to receive dual therapy compared with those &lt;45 years old. Those with hypertension (OR = 8.85, 95% CI 8.45, 9.27), diabetes (OR = 4.10, 95% CI 3.97, 4.23) and heart failure (OR = 1.78, 95% CI 1.72, 1.84) were more likely to receive dual therapy compared with the general population. Significant increases in prescribing were observed only after the CALM (<jats:italic>P<\/jats:italic>= 0.03) and VALIANT (<jats:italic>P<\/jats:italic>= 0.007) trials.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Increased co\u2010prescribing of ACEIs and ARBs was observed in Ireland during 2000\u201309. Prescribing patterns did not appear to be affected by results from major trials.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1365-2125.2010.03835.x","type":"journal-article","created":{"date-parts":[[2010,10,29]],"date-time":"2010-10-29T18:41:21Z","timestamp":1288377681000},"page":"458-466","source":"Crossref","is-referenced-by-count":8,"title":["Trends in co\u2010prescribing of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in Ireland"],"prefix":"10.1111","volume":"71","author":[{"given":"Wan A. H.","family":"Wan Md Adnan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur L.","family":"Zaharan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen","family":"Bennett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine A.","family":"Wall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2011,2]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2007.09.019"},{"key":"e_1_2_7_3_2","article-title":"Renal and cardio\u2010protective effects of direct renin inhibition: a systematic literature review","author":"Heerspink H","year":"2009","journal-title":"J Hypertens"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa010713"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14283-3"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.321.7274.1440"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801317"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)12229-5"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2006.04.077"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa032292"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0828-282X(09)70492-1"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2008.10.036"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1586\/erc.09.47"},{"key":"e_1_2_7_14_2","volume-title":"Finance Shared Services Primary Care Reimbursement Services Statistical Analysis of Claims and Payments 2007","author":"Health Service Executive","year":"2007"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2710.2002.00430.x"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02896.x"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF03169139"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-002-0542-6"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.289.18.2363"},{"key":"e_1_2_7_20_2","volume-title":"Diabetes Atlas","author":"International Diabetes Federation","year":"2008"},{"key":"e_1_2_7_21_2","first-page":"7","volume-title":"Executive Summary","author":"Balanda KP","year":"2010"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa055202"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.earlhumdev.2005.11.001"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.3317\/jraas.2006.011"},{"key":"e_1_2_7_25_2","first-page":"1462","article-title":"2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"28","author":"Mancia G","year":"2007","journal-title":"Eur Heart J"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjr.0000277983.23934.c9"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejheart.2008.08.005"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehn416"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1080\/14017430310014919"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-9842(03)00003-5"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/1099-1557(200007\/08)9:4<313::AID-PDS508>3.0.CO;2-F"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2710.2008.00875.x"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2005.02478.x"},{"key":"e_1_2_7_34_2","first-page":"188","article-title":"Epidemiology and economics of statin use","volume":"101","author":"Feely J","year":"2008","journal-title":"Ir Med J"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61236-2"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.2215\/CJN.03350708"},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/0895-4356(92)90016-G"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1258\/135581905774414259"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/ageing\/afl106"},{"key":"e_1_2_7_40_2","first-page":"459","article-title":"How common is heart failure? Evidence from PACT (prescribing analysis and cost) data in Nottingham","volume":"17","author":"Clarke K","year":"1995","journal-title":"J Public Health Med"},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1388-9842(03)00046-1"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cmn105"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2004.02179.x"},{"key":"e_1_2_7_44_2","first-page":"169","article-title":"Inequalities in prescribing of secondary preventative therapies for ischaemic heart disease in Ireland","volume":"95","author":"Bennett K","year":"2002","journal-title":"Ir Med J"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2125.2010.03835.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2125.2010.03835.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T00:20:46Z","timestamp":1697415646000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2125.2010.03835.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,2]]},"references-count":43,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["10.1111\/j.1365-2125.2010.03835.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2125.2010.03835.x","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2]]}}}